摘要
多发性骨髓瘤(MM)是浆细胞异常增生的恶性肿瘤,发病率位于血液系统肿瘤的第2位,目前仍不能治愈,是预后较差的造血系统疾病,其并发血栓形成的风险较高,尤其是静脉血栓栓塞(VTE)的发生率较一般人群偏高。近年来国内外许多研究证明免疫调节药物对MM的诱导缓解、巩固及维持治疗可获得较好疗效,但也可导致与治疗相关的VTE发生率明显增加。因此关于MM并发VTE的研究成为热点,但发生机制尚不完全清楚,成为临床亟待解决的问题。
Multiple myeloma(MM)is a malignant tumor with abnormal proliferation of plasma cells.Incidence of MM is the second highest among hematological tumors and there is no effective treatment.Thrombogenesis,especially venous thromboembolism(VTE),is a high risk complication in MM patients.Studies have proved the positive effect of immunomodulatory drugs on remission,consolidation and maintenance treatment of MM,but the risk of VTE increases.Pathogenesis of VTE in patients with MM is under research.
作者
高哲
陶洁
Gao Zhe;Tao Jie(Department of Hematology,First Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处
《中国医药》
2019年第5期787-790,共4页
China Medicine
关键词
多发性骨髓瘤
静脉血栓
Multiple myeloma
Venous thromboembolism
